- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01592201
A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug
June 24, 2014 updated by: Janssen Korea, Ltd., Korea
An Open-label, Prospective, Randomized and Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug
The purpose of this study is to compare the patient satisfaction between continued administration of previous antipsychotics versus switched administration to paliperidone ER in non-satisfied patients with previous (paliperidone)
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
This is a randomized (patients are assigned to intervention by chance), prospective, open-label (all people involved know the identity of the assigned drug), switch study designed to evaluate patient-assessed medication satisfaction after 12 weeks of treatment in patients with schizophrenia.
The total duration of this study is 12 weeks.
Outpatients who treated atypical antipsychotics and report dissatisfaction (Medication Satisfaction Questionnaire [MSQ] <4) with their current treatment response are eligible to participate in the study.
Patients will be randomized into two groups, 1) Patients randomized to an immediate initiation of paliperidone ER for a total 12 weeks 2) Patients randomized to a delayed initiation will continue their previous atypical antipsychotics for 8 weeks and then be initiated on paliperidone ER at Day 56 for 4 weeks.
During the study treatment optimization will be done by dose adjustment (dose increase or decrease) and by adding psychotropic agents except the antipsychotics.
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Busan, Korea, Republic of
-
Cheonan City, Korea, Republic of
-
Chuncheon-Si, Korea, Republic of
-
Chungju-Si, Korea, Republic of
-
Dae-Gu, Korea, Republic of
-
Daejeon, Korea, Republic of
-
Goyang-Si, Korea, Republic of
-
Gyeonggi-Do, Korea, Republic of
-
Seoul, Korea, Republic of
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must be diagnosed with schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria
- Have taken atypical antipsychotics (aripiprazole, olanzapine, risperidone) at least 6 weeks prior to start of study.
- Have Medication Satisfaction Questionnaire (MSQ) score of ≤3
- Competent patients who manage to answer the questionnaires
Exclusion Criteria:
- Have had a history or current symptoms of tardive dyskinesia or neuroleptic malignant syndrome
- Have had relevant history of or current presence of any significant or unstable cardiovascular, respiratory, neurological (including seizures or significant cerebrovascular), renal, hepatic, hematologic, endocrine, immunologic, morbid obesity (BMI≥40), or other systemic disease
- Had received two or more different kind of antipsychotics.
- Had a history of taking paliperidone extended release (ER).
- Allergy or hypersensitivity to risperidone or paliperidone ER.
- Have been on clozapine or long-acting injectable antipsychotic medication during the last 3 months.
- Have had Medication Satisfaction Questionnaire (MSQ) score>3
- Have been hospitalized for longer than 8 continuous weeks during the past 6 months
- Had history of any severe preexisting gastrointestinal narrowing (pathologic or iatrogenic) or inability to swallow the oral tolerability medication whole with the aid of water for patients requiring oral tolerability testing
- Current substance dependence (DSM-IV) or past history of dependence (more than 6 months)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Paliperidone ER
Immediate initiation of Paliperidone ER for a total of 12 weeks
|
Form = osmotic release oral system, route = oral
|
EXPERIMENTAL: Antipsychotics and paliperidone ER
Delayed initiation included previous atypical antipsychotics for 8 weeks and then be initiated on paliperidone ER at Day 56 for 4 weeks.
The atypical antipsychotics includes aripiprazole, olanzapine and risperidone.
These antipsychotics belongs to the class of second generation bipolar atypical antipsychotics.
|
Form = osmotic release oral system, route = oral
Form = tablet, route = oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the medication satisfaction questionnaire (MSQ) score at Week 8
Time Frame: Baseline and Week 8
|
A single-item, global, patient-completed instrument that is read aloud to patients by clinicians designed to assess treatment satisfaction among patients with schizophrenia.
It consists of one question: "Overall, how satisfied are you with your current antipsychotic medication(s)?" with responses assessed on a 7-point scale rated as follows: 1 = extremely dissatisfied, 2=very dissatisfied, 3=somewhat dissatisfied, 4=neither satisfied nor dissatisfied, 5=somewhat satisfied, 6 = very satisfied, 7 = extremely satisfied
|
Baseline and Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive and negative symptoms scale (PANSS) score
Time Frame: Baseline to Week 12
|
The PANSS provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each rated on a scale of 1 (absent) to 7 (extreme).
It's designed to capture symptoms of schizophrenia.
(Gold standard)
|
Baseline to Week 12
|
Drug Attitude Inventory (DAI)-10 Score
Time Frame: Baseline to Week 12
|
DAI-10 is a 10-item scale developed to assess how the attitude of schizophrenia patients toward their medications may affect compliance (-10~+10)
|
Baseline to Week 12
|
Clinical Global Impression-Severity (CGI-S) Score
Time Frame: Baseline to Week 12
|
The CGI-S rating scale is used to rate the severity of a patient's psychotic condition on a 7-point scale ranging from 1 (not ill) to 7 (extremely severe)
|
Baseline to Week 12
|
Personal and Social Performance Scale (PSP)
Time Frame: Baseline to Week 12
|
This scale assesses the degree of dysfunction a patient exhibits within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior.
The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (i, absent to vi, very severe) in each of the 4 domains.
Based on the four domains there will be one total score.
Patient's with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; ≤ 30, functioning so poorly as to require intensive supervision
|
Baseline to Week 12
|
Sleep Visual Analog Scale (Sleep VAS)
Time Frame: Baseline to Week 12
|
This self-administered scale rates quality of sleep and daytime drowsiness.
Patient's will indicate on an 11- point scale (from 0 to 10) how well they have slept in the previous 7 days ("very badly" to "very well") and how often they have felt drowsy within the previous 7 days ("not at all" to "all the time").
On the sleep evaluation scale, score '0' corresponds to 'very badly' and score '10' to 'very well'.
On the daytime drowsiness scale, score '0' corresponds to 'not at all' and score '10' to 'all the time
|
Baseline to Week 12
|
Number of patients with adverse events
Time Frame: Baseline to Week 12
|
Baseline to Week 12
|
|
Number of patients with vital signs and physical examination
Time Frame: Baseline to Week 12
|
Baseline to Week 12
|
|
Number of patients with laboratory test (prolactin, blood glucose, glycosylated hemoglobin, cholesterol, triglyceride)
Time Frame: Baseline to Week 12
|
Baseline to Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2012
Primary Completion (ACTUAL)
June 1, 2013
Study Completion (ACTUAL)
June 1, 2013
Study Registration Dates
First Submitted
February 10, 2012
First Submitted That Met QC Criteria
May 3, 2012
First Posted (ESTIMATE)
May 7, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
June 25, 2014
Last Update Submitted That Met QC Criteria
June 24, 2014
Last Verified
June 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agonists
- Dopamine Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Olanzapine
- Aripiprazole
- Risperidone
- Antipsychotic Agents
Other Study ID Numbers
- CR100782
- PAL-KOR-4019 (OTHER: Janssen Korea, Ltd., Korea)
- R076477SCH4064 (OTHER: Janssen Korea, Ltd., Korea)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Rakitzi, StavroulaActive, not recruiting
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on Paliperdidone ER
-
RVL Pharmaceuticals, Inc.Osmotica Pharmaceutical US LLCWithdrawnMultiple Sclerosis | SpermUnited States
-
Rhode Island HospitalCompletedOverweight and ObesityUnited States
-
Columbia UniversityBiolase IncActive, not recruitingPeri-ImplantitisUnited States
-
HealthPartners InstituteTerminated
-
Uppsala UniversityRecruitingADHD | Emotion Regulation | Attention Deficit Disorder With HyperactivitySweden
-
Jewish General HospitalRecruiting
-
Medical University of South CarolinaGeorgia State UniversityCompletedAnxiety Disorders | Stress Disorders, Post-Traumatic | Mental Disorder | Traumatic Stress DisorderUnited States
-
TaiRx, Inc.CompletedAdvanced CancerTaiwan
-
Asieris Pharmaceuticals (AUS) Pty Ltd.Completed
-
Member Companies of the Opioid PMR ConsortiumTerminatedOpioid-Related Disorders | Drug Abuse | Opiate Addiction | Narcotic AbuseUnited States